Treatments with BA (1.7–9.0 mg/kg/day) of nude mice implanted subcutaneously with human prostate adenocarcinoma LNCaP cells showed decreased cell proliferation, tumor size, prostate-specific antigen (PSA) levels and intratumoral expression of IGF-1 [29]. This evidence concerns the gene KLK3 and prostate adenocarcinoma.